Overview Safety & Efficacy of DCR-PHXC in Patients With PH1/2 and ESRD Status: Recruiting Trial end date: 2025-05-01 Target enrollment: Participant gender: Summary The aim of this study is to evaluate DCR-PHXC in participants with PH1 or PH2 and severe renal impairment, with or without dialysis. Phase: Phase 2 Details Lead Sponsor: Dicerna Pharmaceuticals, Inc.